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Medicinal herbs have been used over the past centuries for
restoring the body’s homeostatic balance. Contemporary use
of herbal supplements remains widespread in many cultures
as treatment for speciﬁc ailments. Many possess cardiovas-
cular actions, and some interact with cardiac medications.
However, there is variable scientiﬁc evidence with respect to
their safety and efﬁcacy, and few have been subjected to the
same rigorous evaluation processes and regulations as
contemporary pharmaceuticals (1). In the ﬁeld of heart
failure, we have also witnessed the failure of promising
naturopathic therapies like hawthorn extract in translating
their potential beneﬁts in rigorous clinical trials (2,3).
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In traditional Chinese medicine (TCM), the heart is the
home of spirit or mind (shen). The heart qi is the power for
blood circulation and keeps blood in the vessels, whereas
heart yang can warm organs and promote ﬂuid metabolism.
The fundamental problem in heart failure is the prolonged
deﬁciency of heart qi and yang, which causes the heart to
become too weak to move blood and transport ﬂuid,
leading to blood “stasis” and excessive ﬂuid retention (4).
These pathological factors can inﬂuence each other and
present different symptom patterns. Hence, the treatment
principles are that they collectively invigorate the heart qi
and warm yangdspeciﬁcally by accelerating blood circula-
tion, liberating ﬂow of the network vessels, disinhibiting
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medicine, although their physiological effects may be
difﬁcult to quantify. Regardless, few TCM remedies for
heart failure have been put into scientiﬁcally rigorous
clinical evaluation, and their users are largely conﬁned to
strong believers in TCM.
In this issue of the Journal, Li et al. (5) reported the results of
a double-blind, multicenter, placebo-controlled, prospective,
randomized clinical trial of qili qiangxin capsules in more than
500 patients with systolic heart failure. Qili qiangxin is
a formulation based on several common medicinal herbs in
TCM that are well known to have cardiotonic and immuno-
modulatory effects (6–8). Combined in a capsule form, some
herbs are commonly used in many Chinese households
for everyday food preparations. The researchers reported an
approximately 25% reduction in N-terminal pro–B-type
natriuretic peptide (NT-proBNP) levels and a greater
proportion of patients with 30% reduction in NT-proBNP
levels after 12 weeks of qili qiangxin capsules compared with
placebo (5). These ﬁndings paralleled the improvements in
New York Heart Association functional class, quality of life
scores, and left ventricular ejection fraction (LVEF) observed
in the treatment groupdall without incremental adverse
events (5).
Because few pharmacological therapeutics have crossed the
threshold in delivering much-needed breakthroughs in the
ﬁeld of heart failure over the past decades, the investigators
should be congratulated for conducting a rigorous clinical
trial that encompasses all of the elements of an objective
scientiﬁc evaluation of this TCM patent drug. It is also
reassuring that no substantial harm was observed in
this relatively large sample size, even though the exposure
duration was relatively short (12 weeks). Clearly, larger vali-
dation studies are needed to provide further evidence for its
use, particularly with a broader investigational community.
However, the most obvious question to reconcile is how
a relatively modest (albeit statistically signiﬁcant) short-term
improvement in LVEF in the absence of a signiﬁcant
change in overall left ventricular dimension can translate
into potential long-term beneﬁts of qili qiangxin. Perhaps the
answer lies in the search for the active ingredients of
qili qiangxin. With contemporary mass spectrometry ap-
proaches, a broad range of organic compounds such as tri-
terpenoid saponins, ﬂavonoid glycosides, C21-steroids, and
phenolic acids can be identiﬁed in qili qiangxin capsules (9).
Ginsenosides, often found in ginseng, may modulate the
Naþ/Kþ-ATPase channels, thereby explaining the “cardio-
tonic” properties similar to those found in many conventional
remedies, including digitalis (10). This is an important
cautionary note because several promising drugs with car-
diotonic or metabolic modulation as their pharmacodynamic
proﬁle have emerged over the past decades but did not
demonstrate incremental beneﬁts. For example, treatment
with enoximone produced minimal changes in cardiac
dimensions despite substantial improvements in LVEF and
quality of life (11,12), and enoximone did not demonstrate
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event-driven clinical trials (13).
Another potential insight from the report is the fact that the
study population was composed of largely nonischemic but
symptomatic and well-treated patients (with a mean 6-min
walk distance comparable to that in mild to moderate heart
failure). They were relatively young, with few comorbid
conditions (creatinine: 2.2 mg/dl), and this was consistent
with the fact that these patients had a relatively low event rate
(<10% annualized mortality rate and low heart failure
hospitalization rate) and relatively preserved systolic blood
pressure (mean:>120 mmHg). Nevertheless, the majority of
patients were taking diuretic therapy with a rather high
baseline NT-proBNP level (median: 1,815 pg/ml). It is
therefore conceivable that additional decongestive (diuretic
and/or natriuretic) effects of qili qiangxin may in part account
for the observed reduction in NT-proBNP levels and
improvements in morbidity. Unfortunately, we simply had
too limited information about the background drug regimen
for the study populationdbesides being stable for at least
2 weeks and whether or not dosing of background drugs
had been modiﬁed during the study perioddto draw any
speculations.
We often struggle when faced with new ideas and new
concepts from century-old holistic approaches. Regardless of
the underlying mechanistic underpinnings, the most impor-
tant task is to demonstrate that the approach provides incre-
mental beneﬁts and to learn how to best mitigate the risks. As
Sir William Withering cautioned us from his infamous
Account of the Foxglove, “. it is better the world should derive
some information, however imperfect, from my experience,
than that the lives ofmen should be hazarded by its unguarded
exhibition, or that a medicine of so much efﬁcacy should be
condemned and rejected as dangerous and unmanageable”
(10). The ﬁndings reported by Li et al. (5) have certainly given
us much-needed information to derive some conﬁdence and
may have broken the barrier in establishing clinical evidence,
which few TCM drugs have been able to accomplish.We can
no longer put this therapeutic approach in the category of
testimonial recommendation, even though it is obvious that
muchmore long-term validation data are required. That being
said, the relative concentrations of these ingredients are largely
unknown, even when analyzed with the latest technologies.
Also, like many similar TCM patent drugs, the “active
ingredients” may not be as consistent from one capsule to
another (14). Hence, the struggle with the lack of familiarity
and unknown consistency of the active compounds in qili
qiangxin capsules will like remain the reasons why the results
of this study may be received with cautious optimism. Above
all, the use of a “pre-mix” patent drug like qili qiangxin is in
direct conﬂict with the conventional reductionist approach
of Western medicine, which requires the identiﬁcation and
isolation of the ingredients that provide the therapeutic efﬁ-
cacies. It is conceivable that, in the future, if qili qiangxinproves to provide morbidity and mortality beneﬁts in rigorous
clinical trials, it will fundamentally challenge the existing
foundation of scientiﬁc inquiry based upon the precise
understanding of pharmacodynamics of drug therapies. Yet,
even at present, the promising results reported by Li et al. may
have opened the opportunity to explore with the latest tech-
nologies how synergistic interactions among active TCM
ingredients can beneﬁt the syndrome of heart failure. This is
a challenge that we should all warmly embrace.
Reprint requests and correspondence: Dr. W. H. Wilson Tang,
Department of Cardiovascular Medicine, Cleveland Clinic, 9500
Euclid Avenue, Desk J3-4, Cleveland, Ohio 44195. E-mail:
tangw@ccf.org.
REFERENCES
1. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential
interactions in patients with cardiovascular diseases. J Am Coll Cardiol
2010;55:515–25.
2. Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic
heart failure. Cochrane Database Syst Rev 2008;(1):CD005312.
3. Zick SM, Vautaw BM, Gillespie B, Aaronson KD. Hawthorn Extract
Randomized Blinded Chronic Heart Failure (HERB CHF) trial. Eur J
Heart Fail 2009;11:990–9.
4. Liang D, Zhang M. The thinking on TCM differential treatment of
congestive heart failure. J Tradit Chin Med 2000;20:44–7.
5. Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-
blind, parallel-group, placebo-controlled study of the effects of qili
qiangxin capsules in patients with chronic heart failure. J Am Coll
Cardiol 2013;62:1065–72.
6. Xiao H, Song Y, Li Y, Liao YH, Chen J. Qiliqiangxin regulates the
balance between tumor necrosis factor-alpha and interleukin-10 and
improves cardiac function in rats with myocardial infarction. Cell
Immunol 2009;260:51–5.
7. Liu W, Chen J, Xu T, et al. Qiliqiangxin improves cardiac function in
spontaneously hypertensive rats through the inhibition of cardiac chy-
mase. Am J Hypertens 2012;25:250–60.
8. Zou Y, Lin L, Ye Y, et al. Qiliqiangxin inhibits the development of
cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of
pressure overload in mice. J Cardiovasc Pharmacol 2012;59:268–80.
9. Kang LP, Zhao Y, Yu HS, et al. Identiﬁcation of chemical constituents
in qiliqiangxin capsule by UPLC-Q-TOF/MS(E). Yao Xue Xue Bao
2011;46:1231–6.
10. Withering W. An Account of the Foxglove and Some of Its Medical
Uses: With Practical Remarks on Dropsy and Other Diseases. Bir-
mingham, United Kingdom: M. Sweeny, 1785.
11. Lowes BD, HigginbothamM, Petrovich L, et al. Low-dose enoximone
improves exercise capacity in chronic heart failure. Enoximone Study
Group. J Am Coll Cardiol 2000;36:501–8.
12. Park JW, Heinzler R, Wirtz JH, et al. Low-dose enoximone therapy in
pre-transplant patients: hemodynamic, echocardiographic, and neuro-
humoral ﬁndings. Z Kardiol 1994;83 Suppl 2:49–53.
13. Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral
enoximone administration on mortality, morbidity, and exercise
capacity in patients with advanced heart failure: the randomized,
double-blind, placebo-controlled, parallel group ESSENTIAL trials.
Eur Heart J 2009;30:3015–26.
14. Li X, Chen H, Jia W, Xie G. A metabolomics-based strategy for the
quality control of traditional Chinese medicine: shengmai injection as
a case study. Evid Based Complement Alternat Med 2013;2013:
836179.
Key Words: chronic heart failure - controlled clinical trial - qili qiangxin
capsules.
